MedTrace Logo

Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

NCT01291823 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-02-08

No results posted yet for this study

Summary

Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.

Conditions

  • Esophageal Cancer

Interventions

DRUG

gefitinib

gefitinib 250mg/day

RADIATION

Thoracic radiotherapy

Thoracic radiotherapy 54-60Gy over 30 fraction

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Mao Weimin, MD · Zhejiang Cancer Hospital

  • Xu yaping, MD · 0086-571-88122082

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291823 on ClinicalTrials.gov